Since irregular LOX family expression has been linked to poor prognosis (Table 3), notably in breast, pancreatic, cervical, lung and liver cancer, as well as correlated with clinicopathological features of later stage disease in cervical, gastric and head and neck cancers [77,99,101,105,107,124,125,126,127,128], efforts towards using LOX family members for additional staging, as an indicator of disease progression, or a potential biomarker of response to therapy in solid cancers has increased. Here, LOX is linked to liver cancer.